Zacks Investment Research upgraded shares of Imperva Inc (NYSE:IMPV) from a sell rating to a buy rating in a research note released on Tuesday. They currently have $52.00 price target on the stock.

According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “

A number of other brokerages also recently commented on IMPV. Buckingham Research reaffirmed a neutral rating and issued a $45.00 price target on shares of Imperva in a report on Saturday, October 22nd. BTIG Research reaffirmed a neutral rating on shares of Imperva in a report on Saturday, October 22nd. DA Davidson raised shares of Imperva from a neutral rating to a buy rating and increased their price target for the company from $55.00 to $57.00 in a report on Friday, November 4th. Evercore ISI raised shares of Imperva from a hold rating to a buy rating in a research report on Friday, November 4th. Finally, Macquarie raised shares of Imperva from a neutral rating to an outperform rating in a research report on Friday, November 4th. One analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. Imperva has a consensus rating of Buy and an average target price of $47.86.

Analyst Recommendations for Imperva (NYSE:IMPV)

Imperva (NYSE:IMPV) opened at 44.90 on Tuesday. The company’s 50-day moving average price is $41.34 and its 200-day moving average price is $42.76. Imperva has a one year low of $31.11 and a one year high of $57.24. The stock’s market cap is $1.47 billion.

Imperva (NYSE:IMPV) last released its quarterly earnings data on Wednesday, February 8th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.03 by $0.29. Imperva had a negative net margin of 25.60% and a negative return on equity of 28.37%. The business earned $78.40 million during the quarter, compared to the consensus estimate of $70.22 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The business’s revenue was up 7.8% on a year-over-year basis. Analysts forecast that Imperva will post $0.33 EPS for the current fiscal year.

This report was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this report can be accessed at http://www.watchlistnews.com/imperva-inc-impv-raised-to-buy-at-zacks-investment-research/1121744.html.

In other news, insider Amichai Shulman sold 3,085 shares of Imperva stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $40.00, for a total transaction of $123,400.00. Following the completion of the sale, the insider now directly owns 91,830 shares in the company, valued at $3,673,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mark E. Kraynak sold 1,731 shares of Imperva stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $46.10, for a total transaction of $79,799.10. Following the sale, the senior vice president now owns 3,858 shares of the company’s stock, valued at $177,853.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,986 shares of company stock valued at $470,082. 2.20% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Kornitzer Capital Management Inc. KS increased its stake in Imperva by 31.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 589,560 shares of the company’s stock valued at $25,357,000 after buying an additional 142,700 shares during the last quarter. Jet Capital Investors L P acquired a new position in shares of Imperva during the second quarter valued at about $9,670,000. Oxford Asset Management acquired a new position in shares of Imperva during the second quarter valued at about $5,290,000. UBS Asset Management Americas Inc. boosted its position in shares of Imperva by 13.0% in the second quarter. UBS Asset Management Americas Inc. now owns 13,939 shares of the company’s stock valued at $600,000 after buying an additional 1,600 shares during the period. Finally, Penserra Capital Management LLC boosted its position in shares of Imperva by 28.0% in the second quarter. Penserra Capital Management LLC now owns 775,782 shares of the company’s stock valued at $33,366,000 after buying an additional 169,788 shares during the period. Institutional investors and hedge funds own 92.72% of the company’s stock.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.